Follicular lymphoma: Recent and emerging therapies, treatment strategies, and remaining unmet needs Journal Article

Authors: Matasar, M. J.; Luminari, S.; Barr, P. M.; Barta, S. K.; Danilov, A. V.; Hill, B. T.; Phillips, T. J.; Jerkeman, M.; Magagnoli, M.; Nastoupil, L. J.; Persky, D. O.; Okosun, J.
Article Title: Follicular lymphoma: Recent and emerging therapies, treatment strategies, and remaining unmet needs
Abstract: Follicular lymphoma (FL) is a heterogeneous disease with varying prognosis owing to differences in clinical, laboratory, and disease parameters. Although generally considered incurable, prognosis for early- and advanced-stage disease has improved because of therapeutic advances, several of which have resulted from elucidation of the biologic and molecular basis of the disease. The choice of treatment for FL is highly dependent on patient and disease characteristics. Several tools are available for risk stratification, although limitations in their routine clinical use exist. For limited disease, treatment options include radiotherapy, rituximab monotherapy or combination regimens, and surveillance. Treatment of advanced disease is often determined by tumor burden, with surveillance or rituximab considered for low tumor burden and chemoimmunotherapy for high tumor burden disease. Treatment for relapsed or refractory disease is influenced by initial first-line therapy and the duration and quality of the response. Presently, there is no consensus for treatment of patients with early or multiply relapsed disease; however, numerous agents, combination regimens, and transplant options have demonstrated efficacy. Although the number of therapies available to treat FL has increased together with an improved understanding of the underlying biologic basis of disease, the best approach to select the most appropriate treatment strategy for an individual patient at a particular time continues to be elucidated. This review considers prognostication and the evolving treatment landscape of FL, including recent and emergent therapies as well as remaining unmet needs. Implications for Practice: In follicular lymphoma, a personalized approach to management based on disease biology, patient characteristics, and other factors continues to emerge. However, application of current management requires an understanding of the available therapeutic options for first-line treatment and knowledge of current development in therapies for previously untreated and for relapsed or refractory disease. Thus, this work reviews for clinicians the contemporary data in follicular lymphoma, from advances in characterizing disease biology to current treatments and emerging novel therapies. © 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press.
Keywords: signal transduction; survival analysis; gene mutation; overall survival; lenalidomide; neutropenia; cancer recurrence; nonhuman; antineoplastic agents; cancer radiotherapy; rituximab; cancer staging; neoplasms; cancer immunotherapy; progression free survival; immune system; infection; tumor volume; bendamustine; hemoglobin blood level; risk factor; histology; health care quality; epigenetics; cancer size; vorinostat; lactate dehydrogenase; skin disease; radioisotope; radioimmunotherapy; panobinostat; follicular lymphoma; disease exacerbation; non-hodgkin lymphoma; disease surveillance; mocetinostat; diffuse large b cell lymphoma; abexinostat; disease burden; human; priority journal; article; copanlisib; duvelisib; obinutuzumab; tazemetostat; cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine; disease risk assessment; dispersity
Journal Title: The Oncologist
Volume: 24
Issue: 11
ISSN: 1083-7159
Publisher: AlphaMed Press  
Date Published: 2019-11-01
Start Page: e1236
End Page: e1250
Language: English
DOI: 10.1634/theoncologist.2019-0138
PUBMED: 31346132
PROVIDER: scopus
PMCID: PMC6853118
Notes: Article -- Export Date: 2 December 2019 -- Source: Scopus
Citation Impact
MSK Authors
  1. Matthew J Matasar
    151 Matasar
Related MSK Work